Combined Epigenetic Therapy with the Histone Methyltransferase EZH2 Inhibitor 3-deazaneplanocin A and the Histone Deacetylase Inhibitor Panobinostat Against Human AML Cells

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2009 Jul 30

PMID 19638619

Citations 173

Authors

Warren Fiskus

Yongchao Wang

Arun Sreekumar

Kathleen M Buckley

Huidong Shi

Anand Jillella

Celalettin Ustun

Rekha Rao

Pravina Fernandez

Jianguang Chen

Ramesh Balusu

Sanjay Koul

Peter Atadja

Victor E Marquez

Kapil N Bhalla

Affiliations

Soon will be listed here.

Abstract

The polycomb repressive complex (PRC) 2 contains 3 core proteins, EZH2, SUZ12, and EED, in which the SET (suppressor of variegation-enhancer of zeste-trithorax) domain of EZH2 mediates the histone methyltransferase activity. This induces trimethylation of lysine 27 on histone H3, regulates the expression of HOX genes, and promotes proliferation and aggressiveness of neoplastic cells. In this study, we demonstrate that treatment with the S-adenosylhomocysteine hydrolase inhibitor 3-deazaneplanocin A (DZNep) depletes EZH2 levels, and inhibits trimethylation of lysine 27 on histone H3 in the cultured human acute myeloid leukemia (AML) HL-60 and OCI-AML3 cells and in primary AML cells. DZNep treatment induced p16, p21, p27, and FBXO32 while depleting cyclin E and HOXA9 levels. Similar findings were observed after treatment with small interfering RNA to EZH2. In addition, DZNep treatment induced apoptosis in cultured and primary AML cells. Furthermore, compared with treatment with each agent alone, cotreatment with DZNep and the pan-histone deacetylase inhibitor panobinostat caused more depletion of EZH2, induced more apoptosis of AML, but not normal CD34(+) bone marrow progenitor cells, and significantly improved survival of nonobese diabetic/severe combined immunodeficiency mice with HL-60 leukemia. These findings indicate that the combination of DZNep and panobinostat is effective and relatively selective epigenetic therapy against AML cells.

Citing Articles

Targeting the epigenome with advanced delivery strategies for epigenetic modulators.

Guha S, Jagadeesan Y, Pandey M, Mittal A, Chitkara D Bioeng Transl Med. 2025; 10(1):e10710.

PMID: 39801754 PMC: 11711227. DOI: 10.1002/btm2.10710.

The epigenetic role of EZH2 in acute myeloid leukemia.

Fang J, Zhang J, Zhu L, Xin X, Hu H PeerJ. 2024; 12:e18656.

PMID: 39655332 PMC: 11627098. DOI: 10.7717/peerj.18656.

Protein Thermal Stability Changes Induced by the Global Methylation Inhibitor 3-Deazaneplanocin A (DZNep).

Berryhill C, Doud E, Hanquier J, Smith-Kinnaman W, McCourry D, Mosley A Biomolecules. 2024; 14(7).

PMID: 39062531 PMC: 11274605. DOI: 10.3390/biom14070817.

Novel dual-targeting inhibitors of NSD2 and HDAC2 for the treatment of liver cancer: structure-based virtual screening, molecular dynamics simulation, and and biological activity evaluations.

Jin X, Wang Y, Chen J, Niu M, Yang Y, Zhang Q J Enzyme Inhib Med Chem. 2023; 39(1):2289355.

PMID: 38059332 PMC: 11721945. DOI: 10.1080/14756366.2023.2289355.

Hedgehog pathway orchestrates the interplay of histone modifications and tailors combination epigenetic therapies in breast cancer.

Wang X, Xu J, Sun Y, Cao S, Zeng H, Jin N Acta Pharm Sin B. 2023; 13(6):2601-2612.

PMID: 37425067 PMC: 10326305. DOI: 10.1016/j.apsb.2023.03.009.

References

Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G . Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol. 2000; 21(1):224-34. PMC: 88796. DOI: 10.1128/MCB.21.1.224-234.2001. View

Fuks F, Burgers W, Brehm A, Hughes-Davies L, Kouzarides T . DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet. 1999; 24(1):88-91. DOI: 10.1038/71750. View

Bhalla K . Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol. 2005; 23(17):3971-93. DOI: 10.1200/JCO.2005.16.600. View

Simon J, Lange C . Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 2008; 647(1-2):21-9. DOI: 10.1016/j.mrfmmm.2008.07.010. View

Montgomery N, Yee D, Chen A, Kalantry S, Chamberlain S, Otte A . The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation. Curr Biol. 2005; 15(10):942-7. DOI: 10.1016/j.cub.2005.04.051. View

Bachmann I, Halvorsen O, Collett K, Stefansson I, Straume O, Haukaas S . EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2005; 24(2):268-73. DOI: 10.1200/JCO.2005.01.5180. View

Schisler J, Willis M, Patterson C . You spin me round: MaFBx/Atrogin-1 feeds forward on FOXO transcription factors (like a record). Cell Cycle. 2008; 7(4):440-3. DOI: 10.4161/cc.7.4.5451. View

Lawrence H, Fischbach N, Largman C . HOX genes: not just myeloid oncogenes any more. Leukemia. 2005; 19(8):1328-30. DOI: 10.1038/sj.leu.2403816. View

Kondo Y, Shen L, Cheng A, Ahmed S, Boumber Y, Charo C . Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008; 40(6):741-50. DOI: 10.1038/ng.159. View

10.

van Kemenade F, Raaphorst F, Blokzijl T, Fieret E, Hamer K, Satijn D . Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood. 2001; 97(12):3896-901. DOI: 10.1182/blood.v97.12.3896. View

11.

Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y . pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. Genes Dev. 2007; 21(1):49-54. PMC: 1759899. DOI: 10.1101/gad.1499407. View

12.

Bracken A, Pasini D, Capra M, Prosperini E, Colli E, Helin K . EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003; 22(20):5323-35. PMC: 213796. DOI: 10.1093/emboj/cdg542. View

13.

Varambally S, Cao Q, Mani R, Shankar S, Wang X, Ateeq B . Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008; 322(5908):1695-9. PMC: 2684823. DOI: 10.1126/science.1165395. View

14.

Kleer C, Cao Q, Varambally S, Shen R, Ota I, Tomlins S . EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003; 100(20):11606-11. PMC: 208805. DOI: 10.1073/pnas.1933744100. View

15.

Kamminga L, Bystrykh L, de Boer A, Houwer S, Douma J, Weersing E . The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood. 2005; 107(5):2170-9. PMC: 1895717. DOI: 10.1182/blood-2005-09-3585. View

16.

Sasaki M, Yamaguchi J, Itatsu K, Ikeda H, Nakanuma Y . Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. J Pathol. 2008; 215(2):175-83. DOI: 10.1002/path.2345. View

17.

van der Vlag J, Otte A . Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet. 1999; 23(4):474-8. DOI: 10.1038/70602. View

18.

McGarvey K, Greene E, Fahrner J, Jenuwein T, Baylin S . DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2. Cancer Res. 2007; 67(11):5097-102. DOI: 10.1158/0008-5472.CAN-06-2029. View

19.

Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A . Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther. 2006; 5(12):3096-104. DOI: 10.1158/1535-7163.MCT-06-0418. View

20.

Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S . Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood. 2006; 108(2):645-52. DOI: 10.1182/blood-2005-11-4639. View